Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Nov;17(11):e014440.
doi: 10.1161/CIRCINTERVENTIONS.124.014440. Epub 2024 Oct 24.

Symptomatic Benefit of SESAME According to Phenotype

Affiliations

Symptomatic Benefit of SESAME According to Phenotype

Hiroki A Ueyama et al. Circ Cardiovasc Interv. 2024 Nov.
No abstract available

Keywords: aortic valve replacement; hypertrophic cardiomyopathy; left ventricular outflow tract obstruction; transcatheter mitral valve replacement; transcatheter myotomy.

PubMed Disclaimer

Conflict of interest statement

Drs Ueyama, Inci, Lisko, Xie, Byku, Hanzel, Greenbaum, Babaliaros, and Gleason have received institutional research support from Abbott Vascular, Ancora Heart, Edwards Lifesciences, Gore Medical, JenaValve, Medtronic, Polares Medical, Transmural Systems, and 4C Medical. Dr Lederman is coinventors on patent applications, assigned to the National Institutes of Health, for transcatheter electrosurgical devices. Dr Byku has served as a consultant for Edwards Lifesciences and Shockwave Medical. Dr Hanzel has served as a consultant for Medtronic. Dr Greenbaum has served as a consultant to Abbott Vascular, Edwards Lifesciences, Excision Medical, and Medtronic; and has equity interests in Transmural Systems and Excision Medical. Dr Babaliaros has served as a consultant to Abbott Vascular, Edwards Lifesciences, and Medtronic; and has equity interest in Transmural Systems.

Figures

Figure 1:
Figure 1:
Summary of Symptomatic Benefit of SESAME According to Phenotype. (A) Overall population with full imaging and 30-day follow-up stratified by LVOT obstruction. Symptomatic benefit is derived more frequently in those with baseline LVOT obstruction. (B) Pre-TMVR population stratified by LVOT obstruction and mitral valve disease. Patients with mitral stenosis often derived symptomatic benefit from standalone SESAME without TMVR. By contrast, patients with mitral regurgitation only derived symptomatic benefit from SESAME if they had baseline LVOT obstruction. LVOT = left ventricular outflow tract, MR = mitral regurgitation, MS = mitral stenosis, NYHA = New York Heart Association classification, SESAME = Septal Scoring Along the Midline Endocardium, TMVR = transcatheter mitral valve replacement

References

    1. Greenbaum AB, Ueyama HA, Gleason PT, Khan JM, Bruce CG, Halaby RN, Rogers T, Hanzel GS, Xie JX, Byku I, et al. Transcatheter Myotomy to Reduce Left Ventricular Outflow Obstruction. J Am Coll Cardiol. 2024;83:1257–1272. doi: 10.1016/j.jacc.2024.02.007 - DOI - PMC - PubMed
    1. Motamed HE, Roberts WC. Frequency and significance of mitral anular calcium in hypertrophic cardiomyopathy: analysis of 200 necropsy patients. Am J Cardiol. 1987;60:877–884. doi: 10.1016/0002-9149(87)91040-x - DOI - PubMed

LinkOut - more resources